- Home
- NWAX vs SPRY Comparison
NWAX vs SPRY Comparison
Compare NWAX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWAX | SPRY |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.0M | 509.4M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NWAX | SPRY |
|---|---|---|
| Price | $10.17 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 52.9K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.68 | $4.91 |
| 52 Week High | $10.34 | $15.09 |
Technical Indicators
Market Signals| Indicator | NWAX | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 48.72 |
| Support Level | $10.06 | $4.91 |
| Resistance Level | $10.25 | $8.61 |
| Average True Range (ATR) | 0.02 | 0.42 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 57.14 | 84.47 |
Price Performance
Historical ComparisonAbout NWAX New America Acquisition I Corp. Class A Common Stock
New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.